Stratify the risk according to the international MGUS risk model (M protein size, immunoglobulin type, free light chain ratio); follow up serum M protein, free light chain, renal function, blood calcium, and hemoglobin every 6–12 months; if M protein increases, bone marrow plasma cells >10%, or organ damage occurs, consider referral to the hematology department for assessment of progression to Monoclonal Gammopathy of Renal Significance/multiple myeloma. The gene discussed is MYOM2; the disease is plasma cell myeloma.